tbuckley/cabot-search huggingface dataset:
Abstract 5760: Early Detection of Arteriopathy in Metabolic Syndrome by MR Molecular Imaging with Targeted Nanobeacons
Authors: Kejia Cai, Wenjing Huang, Todd A Williams, Shelton D Caruthers, Huiying Zhang, Gregory M Lanza, Samuel A Wickline, Patrick M Winter
Journal: Circulation (2008)

Metabolic syndrome elicits widespread inflammatory changes in vascular structures leading to early atherosclerosis that cannot be detected with classical imaging methods. Because pronounced early angiogenesis within the arterial wall typically accompanies activated inflammatory cells in standard models of atherosclerosis, we hypothesized that the expression of α v β 3 -integrins on neovascular endothelium would provide an abundant and sensitive biomarker of the metabolic vasculopathy. The mildly diabetic JCR:LA-cp rat was used as a model for MR molecular imaging of angiogenesis with α v β 3 -targeted gadolinium nanoparticles (NP). 5 month-old male JCR:LA-cp lean (control) and obese (affected) rats (n=5 each) were studied. The abdominal aorta was imaged with a 3.0 T clinical MRI scanner and a T1w, fat-suppressed, black-blood imaging sequence. Imaging was performed before (BSL) and 2 hours (2 HR) after NP injection (IV, 1.0 ml/kg). Fat suppressed imaging revealed large abdominal fat deposits in the obese rats but not in controls, concordant with elevated cholesterol levels (~2 times higher) in the obese rats (p&lt;0.05). MRI contrast enhancement of angiogenesis in the aortic wall (Figure : top, arrow) in the obese rats was significantly higher than that in the lean rats (bottom, *p&lt;0.05) indicating the widespread presence of neovasculature despite no apparent stenosis. MR molecular imaging of angiogenesis with integrin-targeted nanoparticles may represent a sensitive high-resolution surrogate signal for detecting early metabolic vasculopathy. This research has received full or partial funding support from the American Heart Association, AHA Midwest Affiliate (Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, South Dakota &amp; Wisconsin).
STUDIES ON THE EFFECT OF THE ACTION OF DIGITALIS ON THE OUTPUT OF BLOOD FROM THE HEART. III. 12
Authors: Harold J. Stewart, Alfred E. Cohn
Journal: Journal of Clinical Investigation (1932)

The action of digitalis when given to human beings is still incompletely understood.Investigations, in recent years (1, 2, 3, 4), which have been directed toward elucidating its influence on the behavior of the heart have led to a certain degree of confusion.The analysis of the results which have been obtained shows that inferences which were drawn were in part inexact, due to utilizing the results obtained in one situation, in the normal hearts of dogs for example or in those of human beings, in an explanation of the condition of disease.But beside difficulties in interpretation of this sort, error has also resulted from the use of insufficiently tested meth- ods.This defect in the case of human beings applies, it seems, to the use of the method of Field, Bock, Gildea and Lathrop (5) by certain investigators (1, 6), and to that of Henderson and Haggard (7) by others (8).The opportunity is still open, therefore, to study the minute volume output3 of human hearts under the influence of digitalis when they are normal and also when they are the subjects of heart disease.This study is the more important since the result, observed in analyzing the effect on normal hearts, differs, as it turns out, so profoundly from that which supposedly obtains in enlarged diseased ones.If the two are really the same, fundamental conceptions concerning the circulation in heart failure require radical revision.In this study digitalis was given to six normal individuals on seven occasions.Observations were made of its effect on cardiac output, on 1 A preliminary report of these observations appeared in the
Refining and implementing the Tavistock principles for everybody in health care Commentary: Justice in health care a response to Tavistock
Authors: D. Berwick, F. Davidoff, H. Hiatt, R. Smith, D. M Mirvis, J. E Bailey
Journal: BMJ (2001)

The ethicist Will Gaylin argued that healthcare reform often fails because it attempts technical solutions to ethical problems. 1][4][5][6] They were intended for those who are responsible for the healthcare system, those who work in it, and those who use it.This article describes the origins of the principles, discusses the thinking behind them, considers how they might be used, provides case studies, and reflects on where the venture might go now.
Efficacy of nicotineless non-pharmacologic alternative tool for smoking cessation program using varenicline
Authors: Yu Kasamatsu, K. Yoshinoya, M. Kadoya, Y. Kasamatsu
Journal: European Respiratory Journal (2012)

Background:

Tobacco addiction is associated with not only nicotine dependence but also mental dependence based on the habitual smoking situation (e.g. drink alcohol, after meal). The efficacy of substitute nicotineless non-pharmacologic tool (e.g. nicotineless electronic cigarettes) in these situations for smoking cessation was unclear.

Method:

This prospective observational study aimed to investigate the efficacy of non-pharmacologic alternative tool in patients who were treated with a 12-week outpatients smoking cessation program using varenicline. We screened 180 patients who were treated with the program from March 2010 to February 2012. Tobacco addiction in this study was defined as a condition with both at least five points of the Tobacco Dependence Screener (TDS; Kawakami, et al., 1999) and at least 10 pack year. At the first medical examination, we instructed all the patients to use the nicotineless alternative tool when they urge to smoke. We assessed the success rate of smoking cessation at 12 weeks.

Result:

Of 136 patients were eligible (35 were lost, 9 dropped). The success rate was 77.8%. Eighty patients (58.9%) used alternative tool as we instructed. The success rate of the patients who used alternative tool was significantly higher than that of the patients who didn't use the tool (p<0.001). In multivariable logistic regression analysis, the independent predictors of smoking cessation failure were untreatable side effect (p=0.05) and disuse of alternative tool (p=0.01).

Conclusion:

In outpatients smoking cessation program using varenicline, non-pharmacologic alternative tool was useful for patients who urge to smoke in the habitual smoking situations.
Abstract 3722: The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven renal tumor models
Authors: Naoto Miyajima, Tomoshige Akino, Kunihiko Tsuchiya, Satoru Maruyama, Takashige Abe, Nobuo Shinohara, Katsuya Nonomura, Len Neckers
Journal: Cancer Research (2014)

Abstract Introduction: The proto-oncogene MET is aberrantly activated via overexpression or mutation in numerous cancers including papillary renal carcinoma, making it a prime anti-cancer molecular target. However, the clinical success of MET-directed tyrosine kinase inhibitors (TKI) has been limited due, in part, to mutations in the MET kinase domain that confer therapeutic resistance. Circumventing this problem remains a key challenge to improving durable responses in patients receiving MET-targeted therapy. Small molecule HSP90 inhibitors cause HSP90 to dissociate from its client proteins, resulting in their destabilization and eventual degradation. HSP90 inhibitors have been validated in numerous preclinical tumor models and have shown promising activity in several clinical trials. Given the distinct mechanisms of action of TKI and HSP90 inhibitors, we evaluated the synergistic effects of these two drugs on both TKI-sensitive and TKI-resistant MET-driven tumor models. Methods: We tested efficacy of the MET TKI crizotinib, the HSP90 inhibitor ganetespib and their combination in MKN45, wild-type MET-overexpressed cell line and MET-Y1248H, TKI-resistant mutant MET- verexpressed cell line in vitro. The antitumor efficacy of HSP90 inhibition in vivo was verified in xenograft models. Results: MET is an HSP90-dependent kinase, and we show that HSP90 preferentially interacts with and stabilizes activated MET, whether the activation is ligand-dependent or is a consequence of kinase domain mutation. In contrast, many MET TKI show a preference for the inactive form of the kinase and activating mutations in MET can confer resistance. Combining the HSP90 inhibitor ganetespib with the MET TKI crizotinib achieves synergistic inhibition of MET, its downstream signaling pathways, and tumor growth in TKI-sensitive MET-driven tumor models. Unexpectedly, low-dose ganetespib also partially restores crizotinib sensitivity, in vitro and in vivo, to cells and tumors expressing TKI-resistant MET mutants. Conclusion: Our findings support the use of HSP90 inhibitors to overcome or delay the initiation of resistance to MET TKI, and they provide the basis for clinical evaluation of this combination in patients with MET-driven papillary renal cancer. Citation Format: Naoto Miyajima, Tomoshige Akino, Kunihiko Tsuchiya, Satoru Maruyama, Takashige Abe, Nobuo Shinohara, Katsuya Nonomura, Len Neckers. The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven renal tumor models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3722. doi:10.1158/1538-7445.AM2014-3722
Grey spots in a patient with dystrophic epidermolysis bullosa
Authors: A. Schwieger-Briel, D. Kiritsi, H. Schumann, F. Meiss, K. Technau, L. Bruckner-Tuderman
Journal: British Journal of Dermatology (2010)

Journal Article Grey spots in a patient with dystrophic epidermolysis bullosa Get access A. Schwieger‐Briel, A. Schwieger‐Briel Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, Freiburg 79104, Germany E‐mail: agnes.schwieger@uniklinik‐freiburg.de Search for other works by this author on: Oxford Academic Google Scholar D. Kiritsi, D. Kiritsi Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, Freiburg 79104, Germany E‐mail: agnes.schwieger@uniklinik‐freiburg.de Search for other works by this author on: Oxford Academic Google Scholar H. Schumann, H. Schumann Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, Freiburg 79104, Germany E‐mail: agnes.schwieger@uniklinik‐freiburg.de Search for other works by this author on: Oxford Academic Google Scholar F. Meiss, F. Meiss Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, Freiburg 79104, Germany E‐mail: agnes.schwieger@uniklinik‐freiburg.de Search for other works by this author on: Oxford Academic Google Scholar K. Technau, K. Technau Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, Freiburg 79104, Germany E‐mail: agnes.schwieger@uniklinik‐freiburg.de Search for other works by this author on: Oxford Academic Google Scholar L. Bruckner‐Tuderman L. Bruckner‐Tuderman Department of Dermatology, University Medical Center Freiburg, Hauptstrasse 7, Freiburg 79104, Germany E‐mail: agnes.schwieger@uniklinik‐freiburg.de Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 163, Issue 5, 1 November 2010, Pages 1124–1126, https://doi.org/10.1111/j.1365-2133.2010.09900.x Published: 01 November 2010
The Influence of Thyroid Hormones on In Vitro Erythropoiesis
Authors: William J. Popovic, James E. Brown, John W. Adamson
Journal: Journal of Clinical Investigation (1977)

The erythropoietic effect of various thyroid hormones has been studied using erythroid colony formation by canine marrow cells. Although erythropoietin was required for colony growth, physiologic levels of thyroid hormones significantly enhanced colony numbers. The order of potency of the thyroid compounds in their in vitro erythropoietic effect parallels their known calorigenic potency in vivo, suggesting that the in vitro effect is physiologically relevant. A series of studies linked the mechanism of thyroid action to adrenergic receptors on responsive cells. Propranolol, a global beta-blocker, inhibited thyroid hormone-responsive erythroid colonies. When adrenergic antagonists having different blocking characteristics were added to culture, the thyroid hormone effect was blocked by those compounds having beta(2)-subspecificity. Velocity sedimentation analysis showed that the peak of colony-forming cells which respond to thyroid hormone and the adrenergic agonist, isoproterenol, sedimented at an identical rate (7.54 mm/h), which is slower than the major peak of colony-forming cells responding to erythropoietin alone (8.62 mm/h). These results demonstrate thyroid hormonal enhancement of in vitro erythroid colony growth which appears mediated by a receptor with beta(2)-adrenergic properties. The data suggest that changes in hormone-target cell interaction may occur during states of abnormal thyroid function.
Abstract 14886: The Association Between Acculturation and Hypertension Prevalence among South Asian Immigrants in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study
Authors: Allison Kong, David A Shoham, Holly Kramer, Namratha Kandula
Journal: Circulation (2014)

Introduction: South Asians are the second fastest growing ethnic minority group in the US. Despite a modest body mass index, South Asians have a high and early prevalence of cardiovascular disease risk factors, including high blood pressure (BP). The majority of South Asians are immigrants, thus behavior and lifestyle changes may play a role in the development of elevated BP. This paper examines the hypothesis that greater acculturation is associated with hypertension (HTN) in US South Asians. Methods: We examined baseline data (2010 to 2013) of 906 subjects (54% male; mean age 55 ± 9 years) in the Mediators of Atherosclerosis in South Asians Living In America study. HTN was defined by: systolic BP ≥ 140 mmHg, diastolic BP≥ 90 mmHg, and/or use of hypertensive medication. Acculturation was defined by 4 proxy variables and 1 summary score: place of birth, English language proficiency, length of US residency, traditional South Asian beliefs scale, and a summary score of all 4 variables ranging from 0 to 6 (higher score=more acculturated). Multiple logistic regression was used to study the associations between measures of acculturation and HTN, adjusted for sex, age group and education. Interaction with adjustment variables and significant main effects were examined. Likelihood ratio tests were used for statistical significance. Results: The cohort’s overall prevalence of HTN was 41%. We did not find significant associations between HTN and any acculturation measures except English language proficiency, which was associated with lower odds of HTN (OR=0.70; 95% CI: 0.52-0.95; p=0.02). There were evidence of interactions between English proficiency and age (p=0.08), and English proficiency and education (p=0.09): the odds of HTN were lower in older adults who were proficient in English compared to younger adults who were not (OR=0.69; 95% CI: 0.49-0.98; p=0.038) and in South Asians who were English-proficient and had higher education compared to non-fluent speakers who were less educated (OR=0.55; 95% CI: 0.35-0.87; p=0.011). Conclusion: English language proficiency was associated with lower adjusted odds of HTN in older and more highly educated South Asians. The mechanisms through which language and CVD risk factors are linked deserve further exploration.
<i>BMJ Learning</i> : Benign prostatic hyperplasia: treatment in primary care
Authors: Anand K Patel, Christopher R Chapple
Journal: BMJ (2006)

This article provides information on how to treat patients with lower urinary tract symptoms that are suggestive of bladder outflow obstruction, secondary to benign prostatic hyperplasia How do I treat it?The treatment of lower urinary tract symptoms that are suggestive of bladder outflow obstruction, secondary to benign prostatic hyperplasia, should aim to relieve symptoms and improve quality of life, as well as attempt to prevent progression of clinical disease and the development of complications.These benefits need to be balanced against potential side effects of treatment.
US tightens its defences against BSE
Authors: Scott Gottlieb
Journal: BMJ (2001)

US government officials and the farming industry met last week to discuss whether the United States needs to bolster its defences against bovine spongiform encephalopathy (BSE), which has yet to be detected in US cattle.

The US Department of Agriculture has already made it illegal to bring European cattle and beef products into the country. If the disease did surface, the US government speculates that its spread would be limited because the Food and Drug Administration (FDA) prohibits giving cattle feed that contains dead mammals, which …
MD Visa Waivers
Authors: Mike Mitka
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hair removal using the ruby laser: clinical efficacy in Fitzpatrick skin types I-V and histological changes in epidermal melanocytes
Authors: None Liew, None Grobbelaar, None Gault, None Sanders, None Green, None Linge
Journal: British Journal of Dermatology (1999)

The ruby laser is effective in removing unwanted body hair. The occurrence of cutaneous side‐effects such as blistering, hypopigmentation and hyperpigmentation, however, remains problematic. These side‐effects are more commonly seen in patients with dark coloured skin, which partly explains the relative scarcity of information on the efficacy of ruby laser hair removal in such patients. The mechanisms of the occurrence of these side‐effects are also not known. It was the aim of this study to evaluate the efficacy of ruby laser‐assisted hair removal in patients with Fitzpatrick skin type V in a retrospective clinical study and to evaluate the mechanism of post‐treatment pigmentary change in a prospective clinical study. The percentage reduction in hair density in patients with skin type V was assessed after a variable period following treatment with the Chromos 694 Depilation Ruby Laser, and was compared with the results of those with skin types I–IV. To study the pigmentary change and melanocyte numbers after laser irradiation, ex‐vivo scalp skin and serial patient biopsies were taken and stained with S‐100, dopa oxidase and Masson–Fontana methods. Laser treatment reduced melanocyte numbers as measured by DOPA stain but not by S100. Laser treatment resulted in the clearance of pigment from the epidermis on histology. Ruby laser was shown to be effective in removing unwanted hair from patients with dark coloured skin, but with a higher incidence of cutaneous side‐effects. The occurrence of hypopigmentation after laser irradiation was thought to be due to the suppression of melanogenesis in the epidermis rather than to destruction of the melanocytes.
Abstract 1936: A New Subtype of Human Delta-Storage Pool Deficiency is Associated with a Selective Defect in Platelet Multidrug Resistance Protein 4 (MRP4/ABCC4) Expression
Authors: Gabriele Jedlitschky, Marco Cattaneo, Lena E Lubenow, Dieter Rosskopf, Anna Lecchi, Andrea Artoni, Giovanna Motta, Juliane Niessen, Heyo K Kroemer, Andreas Greinacher
Journal: Circulation (2008)
Heparosan‐Derived Heparan Sulfate/Heparin‐Like Compounds: One Kind of Potential Therapeutic Agents
Authors: Pingli Li, Juzheng Sheng, Yuhong Liu, Juan Li, Jian Liu, Fengshan Wang
Journal: Medicinal Research Reviews (2012)

Heparan sulfate (HS) is a highly sulfated glycosaminoglycan and exists in all animal tissues. HS and heparin are very similar, except that heparin has higher level of sulfation and higher content of iduronic acid. Despite the fact that it is a century-old drug, heparin remains as a top choice for treating thrombotic disorders. Pharmaceutical heparin is derived from porcine intestine or bovine lung via a long supply chain. This supply chain is vulnerable to the contamination of animal pathogens. Therefore, new methods for manufacturing heparin or heparin-like substances devoid of animal tissues have been explored by many researchers, among which, modifications of heparosan, the capsular polysaccharide of Escherichia coli K5 strain, is one of the promising approaches. Heparosan has a structure similar to unmodified backbone of natural HS and heparin. It is feasible to obtain HS or heparin derivatives by modifying heparosan with chemical or enzymatic methods. These derivatives display different biological activities, such as anticoagulant, anti-inflammatory, anticancer, and antiviral activities. This review focuses on the recent studies of synthesis, activity, and structure-activity relationship of HS/heparin-like derivatives prepared from heparosan.
Photoremodeling of Arterial Wall Reduces Restenosis After Balloon Angioplasty in an Atherosclerotic Rabbit Model 11This study was supported in part by a research grant from Global Therapeutics, Inc., Broomfield, Colorado and USCI—Division of Bard, Billerica, Massachusetts.
Authors: Nicholas Kipshidze, Harry Sahota, Richard Komorowski, Victor Nikolaychik, Michael H Keelan
Journal: Journal of the American College of Cardiology (1998)
Safety of Urinary Catheters
Authors: James R. Johnson
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal